Panbela Therapeutics, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing disruptive therapies for pressing unmet medical needs in oncology. The company's pipeline leverages a polyamine metabolic inhibitor (PMI) platform to address dysregulated biological processes often observed in aggressive cancers and rare diseases. Its primary asset, ivospemin (SBP-101), a proprietary polyamine analogue, is currently undergoing a pivotal Phase 3 ASPIRE trial for the first-line treatment of metastatic pancreatic ductal adenocarcinoma, with an interim analysis anticipated in the initial quarter of 2025. Beyond pancreatic cancer, Panbela is also progressing Flynpovi™, a combination of eflornithine (CPP-1X) and sulindac, in a partnered Phase 3 registration program for familial adenomatous polyposis (FAP), alongside the individual agent CPP-1X. CPP-1X is further being evaluated in a Phase 1 study for STK11 mutant non-small cell lung cancer, with additional explorations in indications such as gastric cancer prevention, neuroblastoma, and Type 1 diabetes. This Minnesota-based organization, established in 2011, reported its Q3 2024 financial results and recently secured a significant financing commitment from Nant Capital to support its ongoing clinical development efforts.
Leap Therapeutics (NASDAQ:LPTX) vs. Panbela Therapeutics (OTCMKTS:PBLA) Head-To-Head Analysis
Panbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call Transcript
Panbela Provides Business Update and Reports Q3 2024 Financial Results
Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call Transcript
Panbela Provides Business Update and Reports Q2 2024 Financial Results
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
Panbela Therapeutics, Inc. (NASDAQ:PBLA) to Post Q2 2024 Earnings of ($2.07) Per Share, HC Wainwright Forecasts
Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript
Panbela Provides Business Update and Reports Q1 2024 Financial Results
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Panbela Announces Poster Presentation at American Association for Cancer Research:
Panbela Announces Transfer to OTCQB Market
Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)